The Latest Cardiac and Vascular News
U.S. FDA granted Investigational Device Exemption (“IDE”) approval to initiate the BACKBEAT pivotal study evaluating AVIM therapy (BackBeat CNT) in hypertensive pacemaker patients BACKBEAT pivotal study on track to start enrollment before the end of 2023, with a mid-2025 target for completion of enrollment Expected operating cash runway sufficient into […]
Caristo’s AI Technology for Coronary Inflammation Measurement and Risk Assessment Can Transform Risk Stratification and Management of Patients PHILADELPHIA, Nov. 13, 2023 /PRNewswire/ — New research, presented today at the American Heart Association’s Late Breaking Science Sessions, has…
DENVER – November 11, 2023 – Cleerly, the company working to create a new standard of care for the diagnosis of heart disease, today announced the TRANSFORM trial at the American Heart Association’s (AHA) 2023 Scientific Sessions. TRANSFORM is a randomized trial – sponsored by Cleerly – that aims to […]
PASADENA, Calif., Nov. 13, 2023 /PRNewswire/ — Ventric Health, a healthcare technology company and medical device provider focused on cardiovascular health, has announced data presented Saturday, November 11, at the American Heart Association (AHA) Scientific Symposium highlighting a pivotal study demonstrating validation of a noninvasive brachial cuff-ECG system for estimation of elevated left ventricular […]
AHA23: Clinics in the U.S. are projected to save more than 400 hours per year using artificial intelligence (AI) applied to LINQ II™ ICMs that reduce false alerts New data presented today at the American Heart Association’s (AHA) Scientific Sessions 2023 show false alert reductions of more than 91% on […]
ANN ARBOR, Mich., Nov. 13, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced the presentation of results from a pre-specified, exploratory analysis of CLEAR Outcomes at the 2023 American Heart Association (AHA) Scientific Sessions. Results were also simultaneously published in Circulation which can be accessed here. “The analysis presented at AHA and […]
WEST CHESTER, Pa., Nov. 13, 2023 /PRNewswire/ — In response to a significant global unmet need in endovascular aortic disease repair (EVAR/TEVAR), VESTECK, Inc. is please to announce continued procedural success conducting 2 additional clinical cases. Professor Dainis Krievins, lead a…
Southlake, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an AI-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that its MyoVista® wavECGTM has been selected by Cardiact Ltd […]
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced financial results for the third quarter ended September 30, 2023. Recent Business Highlights Advanced feasibility and preclinical studies for the cardiac ablation clamp and catheter programs, and expect to file an FDA 510(k) submission for
CLEVELAND, Nov. 13, 2023 /PRNewswire/ — Centerline Biomedical, Inc. (“Centerline”), an innovator in cardiovascular visualization and navigation systems, today announced the appointment of Indrani Egleston to the position of Chief Financial Officer (CFO). Ms. Egleston joins the company…
